During a six-month period in 1980, tuberculosis was detected in 70 patients at our municipal hospital. Clinical and epidemiologic features of the disease continue to reflect those noted decades ago. Management of these patients was complicated by difficulty in confirming the diagnosis and relapse in patients resisting chemotherapy, although organisms resistant to antituberculosis drugs were infrequent. The hospital cost of caring for tuberculous patients was high (mean: $1941.36). As tuberculosis today remains a disease of the poor, costs for its care still are borne by the public. At a time when reduction in Federal support for tuberculosis control is being considered, it is important to realize that the disease remains a serious medical problem and financial burden in the United States.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00000441-198401000-00005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The bronchoalveolar lavage fluid as a marker for pulmonary fibrosis in diffuse parenchymal lung diseases.
Front Immunol
January 2025
Laboratory of Molecular Immunology, Institute of Molecular Biology, Slovak Academy of Sciences, Bratislava, Slovakia.
Introduction: Diffuse parenchymal lung diseases (DPLD) cover heterogeneous types of lung disorders. Among many pathological phenotypes, pulmonary fibrosis is the most devastating and represents a characteristic sign of idiopathic pulmonary fibrosis (IPF). Despite a poor prognosis brought by pulmonary fibrosis, there are no specific diagnostic biomarkers for the initial development of this fatal condition.
View Article and Find Full Text PDFParasitic infection prevalence in tuberculosis patients and their household contacts in the Littoral Region of Cameroon.
Parasite Epidemiol Control
February 2025
Parasites and Vector Biology Research Unit (PAVBRU), Department of Microbiology and Parasitology, University of Buea, Buea, Cameroon.
Background: Parasitic infections are known to suppress the cell mediated immunity that protects against tuberculosis. The status of parasitic infections among bacteriologically confirmed tuberculosis patients and their household contacts in Cameroon is not well established. This study aimed at reporting the status of parasitic infections in TB patients and their household contacts with keen interest in associated risk factors to disease exposure.
View Article and Find Full Text PDFLevel of tuberculosis-related stigma and associated factors in Ugandan communities.
PLoS One
January 2025
Social & Scientific Systems, Inc., a DLH Holdings Company / United States Agency for International Development Strategic Information Technical Support Activity, Kampala, Uganda.
Tuberculosis (TB) stigma remains a significant barrier to TB control efforts globally, especially in countries with a high TB burden. Studies about TB stigma done in Uganda so far have been limited in scope and focused on data collected health facilities. In this study we report TB related stigma at community level for the period 2021/2022.
View Article and Find Full Text PDFPhase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg-IFNα-2a as Treatment for Chronic Hepatitis Delta.
Liver Int
February 2025
Department of Gastroenterology, Hepatology, Endocrinology, and Infectious Diseases, Hannover Medical School, Hannover, Germany.
Background And Aim: Bulevirtide (BLV) leads to beneficial virologic and biochemical responses when given alone to treat hepatitis delta virus (HDV) infection, which causes the most severe form of chronic viral hepatitis. We evaluated 48 weeks of BLV monotherapy, BLV + tenofovir disoproxil fumarate (TDF) and BLV + pegylated interferon alfa-2a (Peg-IFNα-2a), with 24-week follow-up.
Methods: Ninety patients were enrolled into six arms of 15 each (A-F); 60 patients were included in the main randomisation (arms A-D), and 30 patients (arms E-F) were randomised to the extension phase: (A) Peg-IFNα-2a 180 μg once weekly (QW); (B) BLV 2 mg once daily (QD) + Peg-IFNα-2a 180 μg QW; (C) BLV 5 mg QD + Peg-IFNα-2a 180 μg QW; (D) BLV 2 mg QD; (E) BLV 10 mg QD + Peg-IFNα-2a 180 μg QW and (F) BLV 10 mg (5 mg twice daily) + TDF QD.
Trends in tuberculosis mortality among older adults in China, 2004-2021: a Joinpoint regression and age-period-cohort analysis.
Front Public Health
January 2025
Office of Education and Training (Graduate School), Chinese Center for Disease Control and Prevention, Beijing, China.
Background: Tuberculosis (TB) remains a major public health problem in China and globally, particularly among older adults. This study aimed to examine secular trends in TB mortality among older adults in China and the net effects of age, period, and cohort.
Methods: Data from the National Disease Surveillance Points (DSPs) system were analyzed using Joinpoint regression to determine annual changes in TB mortality among individuals aged 60 years and older from 2004 to 2021.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!